



---

**ACTIVE SUBSTANCE IDENTITY AND CONFORMITY ADVISORY**

**Zhejiang Hisun Pharmaceutical Co. Ltd. 46 Waisha Road Jiaojiang District. Taizhou City, Zhejiang, 318000, China**

The ACVM Group has been advised by the European Medicines Authority (EMA) that active substances from Zhejiang Hisun Pharmaceutical Co. Ltd, China may present a risk when used in the manufacture of finished product. This advice follows an audit of the facilities by the national competent authority in Spain which identified significant issues with the Waisha manufacturing site.

Actives of concern include but are not limited to:

**FIPRONIL  
CLORSULON  
PRAZIQUANTEL**

New Zealand Manufacturers of products containing actives sourced from Zhejiang Hisun Pharmaceutical Co. Ltd, Waisha Campus, Yantou Campus and East Factory Campus are advised to:

- 1) Seek alternative supply; and
- 2) Implement increased inspection measures prior to release.

Where sourcing from an alternative site is not possible full analytical testing in accordance with your GMP programme should be conducted, including impurities, residual solvents and microbiological burden (where applicable).

**Contact details**

Ministry for Primary Industries (MPI)  
Regulation and Assurance Branch  
Agricultural Compounds and Veterinary Medicines  
PO Box 2526  
Wellington 6140  
Email: [acvm-recallsandcompliance@mpi.govt.nz](mailto:acvm-recallsandcompliance@mpi.govt.nz)

**ISSUED BY:**

Glen Bradbury  
Manager Agricultural Compounds and Veterinary Medicines  
System Audit, Assurance and Monitoring Directorate

19 OCTOBER 2016